Enlivex Therapeutics Ltd is a biotechnology company focused on developing innovative therapies to harness the body’s immune system to treat a range of serious conditions. The company specializes in the research and development of cell therapy products aimed at modulating the immune response, particularly in the context of autoimmune diseases and other severe health conditions. With a commitment to advancing novel treatments, Enlivex aims to improve patient outcomes through its cutting-edge technological approaches and potential game-changing medical solutions. Read More
ORLANDO, FL / ACCESS Newswire / March 20, 2026 / RedChip Companies will air interviews with Off The Hook YS Inc. (NYSE American:OTH) and Enlivex Ltd. (NASDAQ:ENLV) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, March 21, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.
ORLANDO, FL / ACCESS Newswire / February 9, 2026 / RedChip Companies, an industry leader in investor relations, media, and research for microcap and small-cap companies, today announced that on-demand replays from its Fintech & Digital Asset Treasury Strategy (DATS) Virtual Investor Conference, held February 4, 2026, are now available.
Voluntarily Delisting of Ordinary Shares from Trading on the Tel Aviv Stock Exchange to Promote U.S.-Based Trading, Reduce Administrative Costs of Dual Listing
The listing on one of the world’s largest global cryptocurrency exchanges expands market access and secondary liquidity for Enlivex’s primary digital treasury asset
Nes-Ziona, Israel, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, “Enlivex” or “the Company”), today announced that it will host a virtual fireside chat on Thursday, December 11, 2025 at 11:00 am ET.
Kartoon Studios (NYSE: TOON) announced significant momentum across its global content ecosystem as Mainframe Studios, Toon Media Networks, and its high-profile IP pipeline continue to fuel long-term growth.
Looking for insights into the US markets one hour before the close of the markets on Monday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
Let's have a look at what is happening on the US markets before the opening bell on Monday. Below you can find the top gainers and losers in today's pre-market session.
- Upon the closing of the private placement, Enlivex will adopt the world’s first RAIN prediction markets token digital asset treasury strategy, via RAIN token accumulation.
Nes-Ziona, Israel, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. ( Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced positive six-month efficacy data from the Phase IIa stage of its randomized, multi-country Phase I/II Allocetra™ trial (ENX-CL-05-001) in patients with moderate to severe knee osteoarthritis (OA). The six-month follow-up has now been completed for all patients. The results re-affirm the three-month data reported previously and substantiate the identification of an age-related primary OA responder population.
Ness-Ziona, Israel, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that it will present a late-breaking poster abstract at the American College of Rheumatology (ACR) Convergence 2025, taking place October 24–29 at McCormick Place Convention Center in Chicago, Illinois.
ORLANDO, FLORIDA / ACCESS Newswire / October 3, 2025 / RedChip Companies will air interviews with Enlivex Therapeutics Ltd. (Nasdaq:ENLV) and Lantern Pharma, Inc. (Nasdaq:LTRN) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV this Saturday, October 4, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.
Nes-Ziona, Israel, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, will participate in a live investor webinar, “Advancing Inflammatory Disease Treatment: Insights & Breakthroughs from Enlivex's Knee Osteoarthritis Program,” hosted by D. Boral Capital on September 30, 2025, at 10:00 AM Eastern Time. The discussion will bring together leading key opinion leaders (KOLs) in musculoskeletal disease, alongside Enlivex’s Vice Chairman and D. Boral’s Research Director. The September 30 KOL webinar will explore recent breakthroughs in treatment approaches discussing the positive Phase IIa topline data from Enlivex’s Allocetra™ program in moderate-to-severe knee osteoarthritis (KOA) patients. Data demonstrated clinically meaningful and highly statistically significant reduction in pain and improvements in function in idiopathic, age-related knee osteoarthritis patients, a large, underserved population.
ORLANDO, FLORIDA / ACCESS Newswire / September 19, 2025 / RedChip Companies will air interviews with Enlivex Therapeutics Ltd. (Nasdaq:ENLV) and 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV this Saturday, September 20, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.
Nes-Ziona, Israel, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced the issuance of an Israeli patent, numbered 290470, titled, “THERAPEUTIC APOPTOTIC CELLS FOR TREATMENT OF OSTEOARTHRITIS”. The patent will provide Enlivex with added intellectual property protection in Israel through at least 2040 with claims covering methods of using Allocetra™ to treat subjects with osteoarthritis.
Intrigued by the market activity one hour before the close of the markets on Monday? Uncover the key winners and losers of today's session in our insightful analysis.
